Epstein-Barr virus (EBV) infection is a benign disease, which may occasionally be fatal, particularly in children and immunocompromised patients. Epstein-Barr virus infection is rare in elderly subjects and seems to have a self-limited course. A case of fatal liver failure due to chronic active EBV infection in a 75-year-old man is described. The etiology was established postmortem by cellular expression of EBV-DNA in liver and lymphatic tissue. This patient meets the diagnostic criteria of a case definition for a highly probable "severe chronic active EBV syndrome." Either suspected or unsuspected, the long-term prognosis of this syndrome is poor and its mortality high.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.anndiagpath.2007.01.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
[Clinical phenotype of abdominal obesity and dynapenia: Brazilian Longitudinal Study of Aging (ELSI-Brazil)].
Cad Saude Publica
January 2025
Universidade Estadual de Campinas, Campinas, Brasil.
This study aims to examine the prevalence of abdominal obesity-dynapenia phenotype, identified by the presence of abdominal obesity and dynapenia, and understand its associated factors with a representative sample of the Brazilian population. Data were collected from the baseline of the Brazilian Longitudinal Study of Aging (ELSI-Brasil) 2015-2016. Abdominal obesity was determined by a waist-to-height ratio ≥ 0.
View Article and Find Full Text PDFNew PPARα Agonist A190-Loaded Microemulsion for Chemotherapy-Induced Peripheral Neuropathy.
Mol Pharm
January 2025
Department of Pharmaceutics, School of Pharmacy, Virginia Commonwealth University, Richmond, Virginia 23298, United States.
Chemotherapy-induced peripheral neuropathy (CIPN) is a serious side effect of anticancer agents with limited effective preventive or therapeutic interventions. Although fenofibrate, a peroxisome proliferator-activated receptor-alpha (PPARα) agonist, has demonstrated neuroprotective and analgesic properties, its clinical utility is hindered by low receptor affinity, poor subtype selectivity, and suboptimal bioavailability. A190, a highly selective and potent nonfibrate PPARα agonist, offers a promising alternative but is limited by poor aqueous solubility, resulting in reduced oral bioavailability and therapeutic efficacy.
View Article and Find Full Text PDFUndocking of an extensive ciliary network induces proteostasis and cell fate switching resulting in severe primary ciliary dyskinesia.
Sci Transl Med
January 2025
Department of Cell Biology and Physiology, Washington University School of Medicine, Saint Louis, MO 63110, USA.
Article Synopsis
- Primary ciliary dyskinesia (PCD) is a rare genetic disorder linked to chronic respiratory issues, infertility, and problems with body asymmetry, primarily caused by mutations in the CCDC39 and CCDC40 genes.
- Researchers used advanced techniques to investigate how these genetic variants impact cellular functions beyond just causing cilia to stop moving.
- They discovered that the absence of CCDC39/CCDC40 creates a significant loss of over 90 ciliary structural proteins, leading to cilia dysfunction and other cellular issues, suggesting that gene therapy could potentially offer a new treatment strategy for PCD.
Ketogenesis supports hepatic polyunsaturated fatty acid homeostasis via fatty acid elongation.
Sci Adv
January 2025
Division of Molecular Medicine, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, USA.
Ketogenesis is a dynamic metabolic conduit supporting hepatic fat oxidation particularly when carbohydrates are in short supply. Ketone bodies may be recycled into anabolic substrates, but a physiological role for this process has not been identified. Here, we use mass spectrometry-based C-isotope tracing and shotgun lipidomics to establish a link between hepatic ketogenesis and lipid anabolism.
View Article and Find Full Text PDFSmall Molecule Modulators of AMP-Activated Protein Kinase (AMPK) Activity and Their Potential in Cancer Therapy.
J Med Chem
January 2025
Department of Pharmaceutical Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, 12850 East Montview Boulevard, Aurora, Colorado 80045, United States.
AMP-activated protein kinase (AMPK) is a central mediator of cellular metabolism and is activated in direct response to low ATP levels. Activated AMPK inhibits anabolic pathways and promotes catabolic activities that generate ATP through the phosphorylation of multiple target substrates. AMPK is a therapeutic target for activation in several chronic metabolic diseases, and there is increasing interest in targeting AMPK activity in cancer where it can act as a tumor suppressor or conversely it can support cancer cell survival.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!